Von Willebrand factor (vWF) is a multimeric plasma glycoprotein that functions in hemostasis as the initiator of platelet adhesion at the site of vascular injury and as the carrier of the anti-hemophilic factor, factor VIII (FVIII).
| Institute |
|---|
| Versiti Blood Research Institute |
| Cat. #: | 155097 |
|---|---|
| Tool sub type: | Primary antibody |
| Unit size: | 100 ug |
| Research Fields: | Immunology |
| Application: | ELISA ; IF ; IP ; WB |
| Target: | von Willebrand Factor |
| Reactivity: | Dog ; Human |
| Host: | Mouse |
| Class: | Monoclonal |
| Alternate name: | vWf |
|---|---|
| Product description: | Von Willebrand factor (vWF) is a multimeric plasma glycoprotein that functions in hemostasis as the initiator of platelet adhesion at the site of vascular injury and as the carrier of the anti-hemophilic factor, factor VIII (FVIII). Hereditary or acquired defects of VWF lead to von Willebrand disease (vWD), a bleeding diathesis of the skin and mucous membranes, causing nosebleeds, menorrhagia, and gastrointestinal bleeding. |
| Conjugation: | Unconjugated |
| Molecular weight: | 293 kDa |
| Immunogen: | vWf – epitope lies on the C-terminal end of VWF |
| Myeloma used: | P3X63Ag8.653 |
| Target background: | Von Willebrand factor (vWF) is a multimeric plasma glycoprotein that functions in hemostasis as the initiator of platelet adhesion at the site of vascular injury and as the carrier of the anti-hemophilic factor, factor VIII (FVIII). Hereditary or acquired defects of VWF lead to von Willebrand disease (vWD), a bleeding diathesis of the skin and mucous membranes, causing nosebleeds, menorrhagia, and gastrointestinal bleeding. |
|---|
| Format: | Liquid |
|---|---|
| Concentration: | 0.9-1.1 mg/ml |
| Storage buffer: | PBS with 0.02% azide |
| Storage conditions: | -15° C to -25° C |
| Shipping conditions: | Dry ice |
| References: |
Jacobi et al. 2012. Blood. 119(19):4543-53. PMID: 22431572. Haberichter et al. 2005. Blood. 105(1):145-52. PMID: 15331450. Haberichter et al. 2000. Blood. 96(5):1808-15. PMID: 10961880. Rosenberg et al. 1998. J Clin Invest. 101(3):613-24. PMID: 9449695. |
|---|
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151016 | Anti-CyclinA [E72.1] |
Key Info
Anti-CyclinA [E72.1]
|
View Tool | |||||||||||||||||||
| 151029 | Anti-HSVICP8 [11E2] |
Key Info
Anti-HSVICP8 [11E2]
|
View Tool | |||||||||||||||||||
| 151034 | Anti-HSVUL42 [13D11] |
Key Info
Anti-HSVUL42 [13D11]
|
View Tool | |||||||||||||||||||
| 151040 | Anti-CD11 & CD18 [24] |
Key Info
Anti-CD11 & CD18 [24]
|
View Tool | |||||||||||||||||||
| 151020 | Anti-CyclinB1 [V143.1] |
Key Info
Anti-CyclinB1 [V143.1]
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.